Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.48
NAS:HZNP's Cash to Debt is ranked lower than
69% of the 789 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. NAS:HZNP: 0.48 )
Ranked among companies with meaningful Cash to Debt only.
NAS:HZNP' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.92 Max: N/A
Current: 0.48
Equity to Asset 0.41
NAS:HZNP's Equity to Asset is ranked lower than
79% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NAS:HZNP: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
NAS:HZNP' s Equity to Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.45 Max: 0.7
Current: 0.41
-0.77
0.7
Interest Coverage 0.27
NAS:HZNP's Interest Coverage is ranked lower than
99% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.15 vs. NAS:HZNP: 0.27 )
Ranked among companies with meaningful Interest Coverage only.
NAS:HZNP' s Interest Coverage Range Over the Past 10 Years
Min: 0.27  Med: 0.79 Max: 0.79
Current: 0.27
0.27
0.79
F-Score: 5
Z-Score: 1.06
M-Score: -2.44
WACC vs ROIC
9.71%
-3.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 2.29
NAS:HZNP's Operating margin (%) is ranked lower than
67% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.25 vs. NAS:HZNP: 2.29 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:HZNP' s Operating margin (%) Range Over the Past 10 Years
Min: -1841.5  Med: -238.23 Max: 7.31
Current: 2.29
-1841.5
7.31
Net-margin (%) -1.34
NAS:HZNP's Net-margin (%) is ranked lower than
74% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. NAS:HZNP: -1.34 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:HZNP' s Net-margin (%) Range Over the Past 10 Years
Min: -1635.12  Med: -333.61 Max: 5.22
Current: -1.34
-1635.12
5.22
ROE (%) -0.94
NAS:HZNP's ROE (%) is ranked lower than
70% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.55 vs. NAS:HZNP: -0.94 )
Ranked among companies with meaningful ROE (%) only.
NAS:HZNP' s ROE (%) Range Over the Past 10 Years
Min: -523.78  Med: -111.48 Max: 4.27
Current: -0.94
-523.78
4.27
ROA (%) -0.39
NAS:HZNP's ROA (%) is ranked lower than
68% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. NAS:HZNP: -0.39 )
Ranked among companies with meaningful ROA (%) only.
NAS:HZNP' s ROA (%) Range Over the Past 10 Years
Min: -186.55  Med: -63.12 Max: 1.89
Current: -0.39
-186.55
1.89
ROC (Joel Greenblatt) (%) 43.17
NAS:HZNP's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.88 vs. NAS:HZNP: 43.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:HZNP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7948.82  Med: -2664.68 Max: 520.88
Current: 43.17
-7948.82
520.88
Revenue Growth (3Y)(%) 115.50
NAS:HZNP's Revenue Growth (3Y)(%) is ranked higher than
98% of the 609 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NAS:HZNP: 115.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:HZNP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -14.5 Max: 115.5
Current: 115.5
0
115.5
» NAS:HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

HZNP Guru Trades in Q4 2015

Julian Robertson 823,577 sh (New)
Joel Greenblatt 2,075,017 sh (New)
Ken Heebner 205,000 sh (New)
Paul Tudor Jones 48,570 sh (+303.47%)
RS Investment Management 2,210,448 sh (+59.77%)
Steve Mandel 15,600,988 sh (unchged)
Steven Cohen Sold Out
Ron Baron Sold Out
Jim Simons 302,400 sh (-35.10%)
» More
Q1 2016

HZNP Guru Trades in Q1 2016

Steven Cohen 1,019,400 sh (New)
Ken Heebner 330,000 sh (+60.98%)
Paul Tudor Jones 72,983 sh (+50.26%)
Julian Robertson 868,477 sh (+5.45%)
Jim Simons Sold Out
Steve Mandel 13,997,232 sh (-10.28%)
RS Investment Management 1,453,024 sh (-34.27%)
Joel Greenblatt 1,053,933 sh (-49.21%)
» More
Q2 2016

HZNP Guru Trades in Q2 2016

Julian Robertson 894,577 sh (+3.01%)
RS Investment Management Sold Out
Ken Heebner Sold Out
Joel Greenblatt Sold Out
Steve Mandel Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 359,800 sh (-64.70%)
» More
Q3 2016

HZNP Guru Trades in Q3 2016

Paul Tudor Jones 49,605 sh (New)
Ken Heebner 1,000,000 sh (New)
Steven Cohen 509,400 sh (+41.58%)
Julian Robertson 673,933 sh (-24.66%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:ENDP, NYSE:CTLT, OTCPK:INVVY, NYSE:PTHN, NAS:AKRX, NAS:MDCO, NAS:NBIX, NAS:IRWD, NAS:RDUS, NYSE:TARO, OTCPK:TSMRF, OTCPK:HKMPF, OTCPK:HYPMY, OTCPK:IPSEY, NAS:DEPO, NAS:EGRX, NAS:PCRX, NAS:SUPN, NAS:IPXL, NYSE:VRX » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC is a specialty pharmaceutical company. The Company's product portfolio consists of ACTIMMUNE, DUEXIS, PENNSAID 2% and RAYOS/LODOTRA, which addresses the unmet therapeutic needs in arthritis, pain, inflammatory and/or orphan diseases.

Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.

Ratios

vs
industry
vs
history
Forward P/E 4.66
HZNP's Forward P/E is ranked higher than
95% of the 63 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.41 vs. HZNP: 4.66 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 54.95
HZNP's Price/Owner Earnings (ttm) is ranked lower than
70% of the 280 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.53 vs. HZNP: 54.95 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
HZNP' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 21.47  Med: 40.79 Max: 85.12
Current: 54.95
21.47
85.12
P/B 2.43
HZNP's P/B is ranked higher than
58% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. HZNP: 2.43 )
Ranked among companies with meaningful P/B only.
HZNP' s P/B Range Over the Past 10 Years
Min: 0.8  Med: 2.29 Max: 14.94
Current: 2.43
0.8
14.94
P/S 3.52
HZNP's P/S is ranked lower than
57% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. HZNP: 3.52 )
Ranked among companies with meaningful P/S only.
HZNP' s P/S Range Over the Past 10 Years
Min: 1.34  Med: 4.08 Max: 12.65
Current: 3.52
1.34
12.65
PFCF 9.28
HZNP's PFCF is ranked higher than
84% of the 197 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.94 vs. HZNP: 9.28 )
Ranked among companies with meaningful PFCF only.
HZNP' s PFCF Range Over the Past 10 Years
Min: 6.89  Med: 18.13 Max: 499.62
Current: 9.28
6.89
499.62
POCF 8.86
HZNP's POCF is ranked higher than
76% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.41 vs. HZNP: 8.86 )
Ranked among companies with meaningful POCF only.
HZNP' s POCF Range Over the Past 10 Years
Min: 6.56  Med: 17.33 Max: 223.97
Current: 8.86
6.56
223.97
EV-to-EBIT 184.25
HZNP's EV-to-EBIT is ranked lower than
97% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.07 vs. HZNP: 184.25 )
Ranked among companies with meaningful EV-to-EBIT only.
HZNP' s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4  Med: -1.6 Max: 219.8
Current: 184.25
-775.4
219.8
EV-to-EBITDA 17.60
HZNP's EV-to-EBITDA is ranked higher than
51% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.70 vs. HZNP: 17.60 )
Ranked among companies with meaningful EV-to-EBITDA only.
HZNP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -608  Med: -0.4 Max: 518
Current: 17.6
-608
518
Current Ratio 2.01
HZNP's Current Ratio is ranked lower than
56% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. HZNP: 2.01 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 2 Max: 4.39
Current: 2.01
0.16
4.39
Quick Ratio 1.72
HZNP's Quick Ratio is ranked lower than
51% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. HZNP: 1.72 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.79 Max: 4.27
Current: 1.72
0.16
4.27
Days Inventory 130.07
HZNP's Days Inventory is ranked lower than
56% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.28 vs. HZNP: 130.07 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s Days Inventory Range Over the Past 10 Years
Min: 13.1  Med: 48.48 Max: 184.95
Current: 130.07
13.1
184.95
Days Sales Outstanding 144.71
HZNP's Days Sales Outstanding is ranked lower than
85% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.78 vs. HZNP: 144.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.08  Med: 89.59 Max: 144.71
Current: 144.71
67.08
144.71
Days Payable 77.07
HZNP's Days Payable is ranked higher than
54% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.88 vs. HZNP: 77.07 )
Ranked among companies with meaningful Days Payable only.
HZNP' s Days Payable Range Over the Past 10 Years
Min: 27.59  Med: 199.62 Max: 410.36
Current: 77.07
27.59
410.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -37.30
HZNP's 3-Year Average Share Buyback Ratio is ranked lower than
90% of the 435 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. HZNP: -37.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HZNP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -428.1  Med: -84.9 Max: 0
Current: -37.3
-428.1
0

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.89
HZNP's Price/Projected FCF is ranked higher than
62% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.77 vs. HZNP: 1.89 )
Ranked among companies with meaningful Price/Projected FCF only.
HZNP' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.73  Med: 3.73 Max: 29.51
Current: 1.89
1.73
29.51
Price/Median PS Value 0.85
HZNP's Price/Median PS Value is ranked higher than
76% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. HZNP: 0.85 )
Ranked among companies with meaningful Price/Median PS Value only.
HZNP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 1.03 Max: 2.77
Current: 0.85
0.39
2.77
Earnings Yield (Greenblatt) (%) 0.58
HZNP's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. HZNP: 0.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HZNP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 0.75 Max: 2.6
Current: 0.58
0.5
2.6

More Statistics

Revenue (TTM) (Mil) $915.3
EPS (TTM) $ -0.08
Beta1.48
Short Percentage of Float12.86%
52-Week Range $13.05 - 23.44
Shares Outstanding (Mil)161.26

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,048 1,359 1,497
EPS ($) 2.01 4.22 3.01
EPS w/o NRI ($) 2.01 4.22 3.01
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Julian Robertson Buys 8 New Stakes in 4th Quarter Mar 09 2016 
Sheets Smith Wealth Management Buys Companies With no Debts Sep 01 2015 
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 

More From Other Websites
What Successful Hedge Funds Think About Worthington Industries, Inc. (WOR) Dec 03 2016
Is SLM Corp (SLM) A Good Stock To Buy? Dec 02 2016
Horizon Pharma upgraded by Citigroup Nov 28 2016
Horizon Pharma Inc (HZNP): Are Hedge Funds Right About This Stock? Nov 25 2016
Nuvo Pharmaceuticals™ Inc. Appoints Jesse Ledger as President Nov 16 2016
HORIZON PHARMA PLC Financials Nov 15 2016
Horizon Pharma PLC (HZNP), Flamel Technologies S.A. (ADR) (FLML) & More: Why Should You Consider... Nov 14 2016
Horizon Pharma plc Presents Data on KRYSTEXXA® (pegloticase) for the Management of Refractory... Nov 14 2016
Horizon Pharma plc Selected as One of Chicago Tribune's 2016 Top Workplaces Nov 11 2016
Horizon Pharma plc Selected as One of Chicago Tribune's 2016 Top Workplaces Nov 11 2016
Horizon Pharma Plc breached its 50 day moving average in a Bullish Manner : HZNP-US : November 11,... Nov 11 2016
Nuvo Pharmaceuticals™ Announces 2016 Third Quarter Results Nov 10 2016
ETF’s with exposure to Horizon Pharma Plc : November 10, 2016 Nov 10 2016
Trump Won: Value Stocks to Buy Now Nov 09 2016
Valeant Pharmaceuticals: Why a Trump Presidency Can't Solve All Its Woes Nov 09 2016
Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016 Nov 09 2016
Horizon Pharma PLC (HZNP) Could Double Its Annual Sales Potential On This Near Term Catalyst Nov 08 2016
Horizon Pharma Plc: Strong price momentum but will it sustain? Nov 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)